Form 4: DexCom Executive Matthew Dolan Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
EVP Matthew Dolan sold 2,423 shares of DexCom stock at $126.58 per share on May 15, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- Matthew Vincent Dolan, EVP of Strategy and Corporate Development at DexCom Inc., sold 2,423 shares of common stock on May 15, 2024.
- The sale was executed at a price of $126.58 per share.
- The transaction was conducted under a pre-existing 10b5-1 trading plan adopted by Mr. Dolan on December 15, 2023.
- Following the transaction, Mr. Dolan beneficially owns 40,075 shares, including unvested restricted stock units and shares purchased through the employee stock purchase plan.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-arranged plan and doesn't indicate any specific positive or negative outlook.
Industry Context
Executive stock sales are a common occurrence, and sales under 10b5-1 plans are often pre-scheduled and don't necessarily reflect a change in the executive's outlook on the company.
Stakeholder Impact
- The sale may have a minor impact on shareholders due to the small volume of shares sold.
Key Dates
| Date | Description |
|---|---|
| 12/15/2023 | Mr. Dolan adopted a 10b5-1 Plan. |
| 03/08/2022 | Grant date for 3,852 restricted stock units vesting through March 8, 2025. |
| 03/08/2023 | Grant date for 14,512 restricted stock units vesting through March 8, 2026. |
| 03/08/2024 | Grant date for 21,711 restricted stock units vesting through March 8, 2027. |
| 05/15/2024 | Date of stock sale transaction. |
| 05/16/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.